Home > WJCD>

Dr. Nagesh S. Anavekar

Department of Cardiology

The Northern Hospital, Australia

Email: nageshsa@unimelb.edu.au


2008  MD, University of Melbourne, Victoria

2007  Fellow of Cardiac Society of Australia and New Zealand (FCSANZ)

2005  Diploma of Diagnostic Ultrasound (DDU), Australian Society of Ultrasound Medicine

2004  Level 3 (Director level) Certification in Echocardiography and cardiac MRI

1995  MB BS (Honors), Monash University, Clayton, Victoria

1989  Victorian Certificate of Education (VCE), Carey Baptist Grammar, Kew, Victoria

Publications (Selected)

  1. Louis WJ, Anavekar NS, Louis SNS, Louis ES, O’Callaghan CJ. Hypertension to heart failure: a global challenge. Cardiovasc. Drugs & Therap. 15(Suppl) : 21,2001.
  2. Iakovidis D, Nero TL, Anavekar NS, Rezman – Vitti LA, Jackman GP, Louis SNS & Louis WJ. Stereospecific synthesis and beta-adrenoreceptor antagonist properties ofS-(-)-1-(4-2-ethoxyethoxy)phenoxy)-2-hydroxy-3(2-(3,4-dimethoxyphenyl)ethylamino)propane hydrochloride, a novel short acting beta 1-specific antagonist. Eur J Med Chem. 2002 Sep; 37(9):731-41.
  3. Anavekar NS, Jackman GP, Horrigan M, O’Callaghan CJ, Louis WJ. Early intravenous beta-blockade using D140S in acute myocardial infarction. Cardiovasc. Drugs & Therap (May 2002); 38(6):634-39.
  4. Solomon SD, Anavekar NS, Greaves S, Rouleau JL, Hennekens C, Pfeffer MA. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodelling. J Am Coll Cardiol. 2004 May 5th; 43(9):1511-14.
  5. Anavekar NS, McMurray J, Velazquez E et al. Relationship between renal function and cardiovascular outcomes. New England Journal of Medicine. 2004 Sep 23;351(13):1285-95.
  6. Anavekar NS, Gans D, Cooper W, Pfeffer MA et al. Predictors of Cardiovascular outcomes in patients with type diabetic nephropathy and hypertension. Kidney International. 2004 Nov(92): S50-55.
  7. Anavekar NS, Pfeffer MA. Cardiovascular Risk and Chronic Kidney Disease. Kidney International. 2004 Nov(92): S11-15.
  8. Anavekar NS, McMurray JJV, Pfeffer MA. Chronic renal disease and cardiovascular risk. New England Journal of Medicine. 2005 Jan 13;352(2):199-200.
  9. Anavekar NS, Solomon SD.Angiotensin II receptor blockade and ventricular remodelling. J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):43-8.
  10. S Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005 Jun 28;111(25):3411-9. 26
  11. Anavekar NS. Cardiovascular Magnetic Resonance Imaging. Heart Lung Circ. 2005;14 Suppl 2:S39-45
  12. Anavekar NS, Anavekar NS. Clinical modifiers for heart failure following myocardial infarction. Curr Heart Fail Rep. 2005 Dec;2(4):165-73.
  13. Anavekar NS, Bais R, Carney S, Davidson J, Eris J, Gallagher M, Johnson D, Jones G, Sikaris K, Lonergan M, Ludlow M, Mackie J, Mathew T, May S, McBride G, Meerkin M, Peake M, Power D, Snelling P, Voss D, Walker R; The Australian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Clin Biochem Rev. 2005 Aug;26(3):81-6
  14. Solomon SD, Anavekar NS. A brief overview of the renin-angiotensin system: emphasis on blockade of the Angiotensin II Type-1 receptor. Medscape Cardiology. 2005; 9(1):1-6.
  15. Anavekar NS, Bais R, Carney S, Davidson J, Eris J, Gallagher M, Johnson D, Jones G, Sikaris K, Lonergan M, Ludlow M, Mackie J, Mathew T, May S, McBride G, Meerkin M, Peake M, Power D, Snelling P, Voss D, Walker R; Routine reporting of eGFR – Laboratory implementation guidelines. Medical Journal of Australia. 2005;183:138-141.
  16. Anavekar NS, Mirza A, Skali H, Plappert T, St John Sutton M, Pfeffer MA, Solomon SD; Survival and Ventricular Enlargement (SAVE) Investigators. Risk assessment in patients with depressed left ventricular function after myocardial infarction using the myocardial performance index--Survival and Ventricular Enlargement (SAVE) experience. J Am Soc Echocardiogr. 2006 Jan;19(1):28-33.
  17. Yerra L, Anavekar NS, Skali H, Zelenkofske S, Velazquez E, McMurray J, Pfeffer M, Solomon SD. Association of QRS duration and outcomes after myocardial infarction: the VALIANT trial.Heart Rhythm. 2006 Mar;3(3):313-6.
  18. Thune JJ, Kober L, Pfeffer MA, Skali H, Anavekar NS, Bourgoun M, Ghali JK, Arnold JM, Velazquez EJ, Solomon SD. Comparison of regional versus global assessment of left ventricular function in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction: the valsartan in acute myocardial infarction echocardiographic study. J Am Soc Echocardiogr. 2006 Dec;19(12):1462-5.
  19. Yan AT, Gibson CM, Larose E, Anavekar NS, Tsang S, Solomon SD, Reynolds G, Kwong RY. Characterization of microvascular dysfunction after acute myocardial infarction by cardiovascular magnetic resonance first-pass perfusion and late gadolinium enhancement imaging. J Cardiovasc Magn Reson. 2006;8(6):831-7.